^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Opdivo Qvantig (nivolumab and hyaluronidase-nvhy)

    i
    Other names: BMS-986298, BMS-986298/rHuPH20, Opdivo SC, ONO-4538HSC, BMS986298, BMS 986298, ONO4538HSC, ONO 4538HSC
    Associations

    News

    Trials
    Company:
    BMS, Halozyme, Ono Pharma
    Drug class:
    PD1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    5ms
    A Phase I Study of ONO-4538HSC in Subjects With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=31, Active, not recruiting, Ono Pharmaceutical Co. Ltd | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Opdivo Qvantig (nivolumab and hyaluronidase-nvhy)
    5ms
    CheckMate-1533: A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=76, Recruiting, Bristol-Myers Squibb | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • Yervoy (ipilimumab) • carboplatin • paclitaxel • pemetrexed • Opdivo Qvantig (nivolumab and hyaluronidase-nvhy)
    6ms
    CheckMate 67T: A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread (clinicaltrials.gov)
    P3, N=632, Active, not recruiting, Bristol-Myers Squibb | Trial completion date: Jan 2026 --> May 2027
    Trial completion date • Head-to-Head
    |
    Opdivo (nivolumab) • Opdivo Qvantig (nivolumab and hyaluronidase-nvhy)
    7ms
    CheckMate-1533: A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=76, Not yet recruiting, Bristol-Myers Squibb
    New P2 trial
    |
    cisplatin • Yervoy (ipilimumab) • carboplatin • paclitaxel • pemetrexed • Opdivo Qvantig (nivolumab and hyaluronidase-nvhy)
    8ms
    A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations (clinicaltrials.gov)
    P2, N=100, Active, not recruiting, Bristol-Myers Squibb | Trial primary completion date: Aug 2025 --> Apr 2025
    Trial primary completion date
    |
    Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw) • Opdivo Qvantig (nivolumab and hyaluronidase-nvhy)
    9ms
    CheckMate 67T: A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread (clinicaltrials.gov)
    P3, N=632, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting
    Enrollment closed • Head-to-Head
    |
    Opdivo (nivolumab) • Opdivo Qvantig (nivolumab and hyaluronidase-nvhy)
    10ms
    CA236-0001: A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=413, Recruiting, Bristol-Myers Squibb | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • Opdualag (nivolumab/relatlimab-rmbw) • Opdivo Qvantig (nivolumab and hyaluronidase-nvhy)
    12ms
    A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations (clinicaltrials.gov)
    P2, N=100, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw) • Opdivo Qvantig (nivolumab and hyaluronidase-nvhy)
    12ms
    CheckMate 8KX: A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20) (clinicaltrials.gov)
    P1/2, N=139, Completed, Bristol-Myers Squibb | Active, not recruiting --> Completed
    Trial completion • Pan tumor
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Opdivo (nivolumab) • Opdivo Qvantig (nivolumab and hyaluronidase-nvhy)
    1year
    A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=413, Not yet recruiting, Bristol-Myers Squibb
    New P1/2 trial • Combination therapy • Metastases
    |
    Avastin (bevacizumab) • Opdualag (nivolumab/relatlimab-rmbw) • Opdivo Qvantig (nivolumab and hyaluronidase-nvhy)
    over1year
    A Phase I Study of ONO-4538HSC in Subjects With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=31, Recruiting, Ono Pharmaceutical Co. Ltd
    New P1 trial • Metastases
    |
    Opdivo Qvantig (nivolumab and hyaluronidase-nvhy)
    over1year
    CheckMate 8KX: A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20) (clinicaltrials.gov)
    P1/2, N=140, Active, not recruiting, Bristol-Myers Squibb | Trial completion date: Mar 2025 --> Sep 2024
    Trial completion date • Pan tumor
    |
    MSI (Microsatellite instability)
    |
    Opdivo (nivolumab) • Opdivo Qvantig (nivolumab and hyaluronidase-nvhy)